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Severe mental illness and European COVID-19 vaccination 
strategies
The EU advises prioritising vaccination for people 
whose health makes them particularly at risk for severe 
COVID-19, but leaves it to member states to decide 
which medical conditions get prioritised. Ethical, 
neuroscientific, and public health considerations have 
been used to prioritise individuals with severe mental 
illness (ie, psychotic disorders, bipolar disorders, and 
severe major depressive disorders).1–3 We systematically 
reviewed national COVID-19 vaccine deployment plans 
across 20 European countries (appendix p 1–2).
Eight of 20 countries explicitly mentioned psychiatry 
or mental illness in their national vaccine strategy 
documents. Several countries prioritised institutional 
residents, which can include people with severe mental 
illness (table). Only four countries (Denmark, Germany, 
the Netherlands, and the UK) had some form of 
higher vaccination priority for outpatients with severe 
mental illness. Additionally, Latvia, Romania, Spain, 
and Sweden prioritised outpatients with disabilities, 
possibly including severe mental illness, whereas the 
Czech Republic and Sweden specified behavioural or 
mental problems interfering with pandemic regulation 
adherence as priority indication.
A European Centre for Disease Control and Prevention 
survey found that most European countries used a 
combination of epidemiological data, mathematical 
modelling, guidelines, ethical considerations, and pub-
lished research to define specific morbidities for vaccine 
prioritisation.4 Here, we present four examples (from 
(the Netherlands, UK, Denmark, and Germany) of 
different approaches that have positive outcomes for 
severe mental illness.
First, the UK used an Oxford University evidence-
based algorithm to calculate the number of vaccinations 
needed to prevent one death.5 Importantly, this QCovid 
algorithm (University of Oxford, UK), based on UK data 
from Jan 24 to June 30, 2020, explicitly includes severe 
mental illness among its risk predictors, and so does 
the UK vaccination strategy. However, preliminary data 
(which had not been peer reviewed as of Feb 11, 2021) 
suggest that vaccination coverage for patients with 
severe mental illness is lagging behind that of other 
comorbidity groups.6
Denmark, Germany, and the Netherlands initially 
omitted mental disorders from their COVID-19 vac-
cination strategies. After a large nationwide Danish 
cohort study found that an increased risk for 
30-day mortality was associated with severe mental 
illness (adjusted OR 2·5, 95% CI 1·2–5·1) and use of 
antipsychotics (adjusted OR 3·3, 95% CI 2·3–4·8),7 the 
Danish Health Authority urged health-care practitioners 
to refer for priority vaccination patients with psychotic 
disorders and other individuals with complex severe 
mental illness deemed to be at particularly high risk 
by the treating physician. Similarly, the Netherlands 
increased prioritisation of patients with severe men-
tal illness following advocacy from mental health 
associations.8
The German federal research institute per formed an 
umbrella review of published systematic reviews and 
meta-analyses to inform the federal Ministry of Health’s 
selection of risk comorbidites.9 However, evidence on 
psychiatric morbidity had not yet been systematically 
summarised at that time and was therefore not 
included in the original strategy. Following an update 
of its literature review, in which severe mental illness 
was found to be one of the few medical comorbidities 
with OR more than 2·0 for COVID-19 hospitalisation 
and mortality, the new strategy now explicitly includes 
severe mental illness in the highest risk group of 
medical comorbidities.9
Multiple high-quality studies have shown odds ratios 
for comorbid severe mental illness, and schizophrenia 
in particular, to equal or even surpass those of 
other risk comorbidities included for prioritisation 
(table).7,10 Evidence-based policy would then require 
severe mental illness to be included in the list of risk 
comorbidities. Yet several sources of bias may have 
caused the risks associated with severe mental illness 
to be overlooked by most countries. Mental disorders 
are often not included as predictors in COVID-19 
outcome studies. Studies specifically inves tigating 
the risks of psychiatric comorbidity have not yet been 
summarised in systematic reviews or meta-analyses and 
were therefore ignored by some national strategies and 
mathematical models. 
See Online for appendix
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Information collected in our report is not definitive 
or exhaustive. Countries are still developing vac-
cination plans and strategies can change as knowledge 
evolves. EU member states have been asked to share 
best practices for prioritisation through the Health 
Security Committee, coordinated by the European 
Commission.
In summary, European countries’ vaccination strat-
egies try to balance ethical and scientific evidence, but 
for individuals with severe men tal illness an evidence-
policy disconnect remains. Most of these patients 
are treated in the community, and are currently 
overlooked by the majority of European COVID-19 
vaccination strategies. Our joint recommendations, 
rep resenting professionals, patients, and families, are 
clear and urgent: explicit inclusion of both inpatients 
and outpatients with severe mental illness in priority 
groups for COVID-19 vaccination, meaningful patient 
and family organisational participation in developing 
vac cination plans, and engagement of peer workers 
in providing vaccination education to patients. We 
therefore call on the European authorities (Council, 
Parliament, and Commission), national health author-
ities, and the scientific community to take note of the 
summarised evidence and our recommendations, and to 
correct this intolerable inequality.
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